Hamid Chalian MD, Abstract Co-Author: Nothing to Disclose

James K. O'Donnell MD, Abstract Co-Author: Research support, Koninklijke Philips NV Research support, Eli Lilly and Company Speakers Bureau, Astellas Group Speakers Bureau, Bayer AG Advisory Board, Eli Lilly and Company Advisory Board, Navidea Biopharmaceuticals, Inc

Prabhakar Rajiah MD, FRCR, Presenter: Institutional Research Grant, Koninklijke Philips NV

1. To understand the roles of PET and MRI in the evaluation of cardiovascular diseases. 2. To discuss the complementary information provided by PET and MRI 3. To recognize that MRI has high spatial and contrast resolution, whereas PET provides metabolic information 4. To illustrate the utility of PET and MRI in several cardiovascular diseases.  

1) Myocardial infarction- Matched Rb/FDG PET defect; Delayed enhancement in MRI 2) Hibernating myocardium- Mismatched defect; No enhancement in MRI; Low function 3) Sarcoidosis- FDG uptake; Non ischemic enhancement 4) Non ischemic cardiomyopathy- FDG uptake; Non ischemic enhancement 5) Tumors- Metastasis, Sarcoma, lymphoma- FDG uptake in malignant tumors; MRI for tissue characterization, contrast enhancement 6) Arteritis- FDG uptake in wall; High signal, delayed enhancement in MRI 7) Abscess- FDG uptake; High signal in MRI 8) Plaque imaging- FDG uptake in inflamed plaque 9) Miscellaneous- Lipomatous hypertrophy of septum, brown fat  

http://abstract.rsna.org/uploads/2014/14000246/14000246_da9p.pdf

Chalian, H, O'Donnell, J, Rajiah, P, Incremental Value of PET and MRI in the Evaluation of Cardiovascular Abnormalities .  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14000246.html